Regulation of cancer cell metabolism:oncogenic MYC in the driver’s seat  

作　　者：Yang Dong Rongfu Tu Hudan Liu Guoliang Qing 

机构地区：[1]Department of Urology,Zhongnan Hospital of Wuhan University,Wuhan 430071,China [2]Frontier Science Center for Immunology&Metabolism,Medical Research Institute,Wuhan University,Wuhan 430071,China

出　　处：《Signal Transduction and Targeted Therapy》2020年第1期1419-1429,共11页信号转导与靶向治疗（英文）

基　　金：supported by the National Science Fund for Distinguished Young Scholars(Grant 81725013 to G.Q.);the National Natural Science Foundation of China(Grant 81830084 to G.Q);the Fundamental Research Funds for the Central Universities(Grant 2042020kf0215);Medical Science Advancement Program(Basic Medical Sciences)of Wuhan University(Grant TFJC2018005 to G.Q.).

摘　　要：Cancer cells must rewire cellular metabolism to satisfy the demands of unbridled growth and proliferation.As such,most human cancers differ from normal counterpart tissues by a plethora of energetic and metabolic reprogramming.Transcription factors of the MYC family are deregulated in up to 70%of all human cancers through a variety of mechanisms.Oncogenic levels of MYC regulates almost every aspect of cellular metabolism,a recently revisited hallmark of cancer development.Meanwhile,unrestrained growth in response to oncogenic MYC expression creates dependency on MYC-driven metabolic pathways,which in principle provides novel targets for development of effective cancer therapeutics.In the current review,we summarize the significant progress made toward understanding how MYC deregulation fuels metabolic rewiring in malignant transformation.

关 键 词：METABOLISM CANCER CANCER 

分 类 号：R73[医药卫生—肿瘤]